Post Cycle Therapy (PCT) is the most crucial aspect of using anabolic steroids.
From the 1950s to the 1970s, the concept of PCT didn’t exist due to a poor understanding of the mechanisms behind anabolic steroids.
It wasn’t until the late 1980s and early 1990s that doctors, scientists, and users began to understand the effects of steroids on the endocrine system.
It was discovered that steroid use suppresses the Hypothalamic-Pituitary-Testicular Axis (HPTA), halting endogenous testosterone production, but the methods to address this were limited at the time.
Today, our scientific and medical understanding of hormonal recovery after steroid use has advanced significantly.
With various recovery drugs and knowledge, it’s possible to minimize side effects on the endocrine system, maintain muscle gains in most cases, and return to a healthy HPTA.
After a steroid cycle, a “hormonal crash” occurs, where testosterone, LH, and FSH levels are suppressed.
This leads to low testosterone and relatively high estrogen and cortisol levels, increasing the risk of muscle loss.
Additionally, SHBG levels rise, deactivating sex hormones.
Although the body can recover on its own, it can take 1 to 4 months, during which muscle loss can occur.
Using testosterone-stimulating agents for rapid hormonal recovery is crucial; neglecting this poses a risk of long-term endocrine damage.
PCT promotes a speedy HPTA recovery and prevents permanent damage, prioritizing endocrine health over muscle preservation.
What Post Cycle Therapy Protocol Should Be Used?
Over the years, various types of PCT protocols have been developed, and the multitude of opinions and established protocols can be confusing for newcomers.
This article will present the most efficient Post Cycle Therapy protocol based on scientific data and logical reasoning.
It will also correct common misconceptions and explain a proper PCT protocol aligned with the latest scientific understanding.
Many anabolic steroid users still follow old, inefficient PCT protocols, which can pose risks not only to them but also to those who learn from them.
Serious problems can arise without a proper understanding of what happens to the endocrine system during PCT, which drugs to use, and the role and application of each.
The HPTA (Hypothalamic-Pituitary-Testicular Axis) is an interconnected system of endocrine glands that regulates testosterone production.
The HPTA controls the production and circulation of testosterone in the body.
Genetics (DNA) is the most critical factor determining the maximum potential for testosterone production, but age, diet, body composition, lifestyle, and physical activity also play a role.
The HPTA maintains balance through a negative feedback loop, reducing testosterone production when levels are too high and increasing it when they are too low.
This feedback loop is regulated by the hypothalamus and works to maintain homeostasis in the endocrine and hormonal systems.
During PCT, the HPTA’s negative feedback loop is a particular concern.
The five key hormones that need to be managed within the HPTA during PCT are GnRH, LH, FSH, Testosterone, and Estrogen.
The HPTA begins in the hypothalamus, which releases GnRH to signal the pituitary gland to produce LH and FSH.
These hormones then signal the testes to stimulate testosterone production.
The primary factors that inhibit testosterone production in the HPTA are excess testosterone and estrogen.
When the hypothalamus detects an excess of these hormones, it suppresses the production of GnRH, LH, and FSH, thereby reducing testosterone production.
The recovery of these signaling hormones can take several months, making it crucial to understand and manage this process with a proper PCT program.
Determining the Factors That Complicate HPTA Recovery
The difficulty of HPTA and endogenous testosterone recovery during PCT is determined by several factors.
Although not in order of importance, the main factors are as follows.
1. Individual Response
Every individual responds differently to chemicals, drugs, and anabolic steroids.
Some may experience minimal HPTA suppression or shutdown, while others may require a very long time to recover.
This depends on how the HPTA is genetically programmed to maintain homeostasis.
2. Type of Anabolic Steroids Used
All anabolic steroids suppress or shut down the HPTA, but the degree of suppression varies.
Some steroids cause mild suppression, while others are highly suppressive.
With prolonged use of any anabolic steroid, the HPTA will eventually be completely shut down or severely suppressed.
3. Cycle Length (Degree of Testicular Desensitization)
The longer the duration of use, the longer the Leydig cells in the testes remain inactive.
A prolonged period of inactivity makes it harder for them to respond to LH and FSH stimulation.
Studies suggest this is not due to a lack of LH but because the Leydig cells have become desensitized.
In one study, LH levels were suppressed after 21 weeks of exogenous testosterone administration. Even when LH levels rose just 3 weeks after cessation, testosterone levels did not increase immediately.
The Three Primary Testosterone-Stimulating Agents for HPTA Recovery During PCT
Using only a single drug for hormonal recovery after an anabolic steroid cycle is not adequate.
For an effective and rapid HPTA recovery, a multi-compound PCT program is ideal.
This program includes the three types of drugs listed below.
SERMs (Selective Estrogen Receptor Modulators), Aromatase Inhibitors, and HCG (Human Chorionic Gonadotropin).
SERMs
The most common SERMs are Nolvadex (Tamoxifen), Clomid (Clomiphene), Raloxifene, and Fareston (Toremifene).
SERMs block or increase the effects of estrogen in specific tissues, which can have positive or negative impacts due to this dual action.
For example, Nolvadex improves cholesterol profiles in the liver and reduces the effects of estrogen in breast tissue, preventing gynecomastia.
It also acts as an estrogen antagonist in the pituitary gland, promoting the release of LH and FSH and aiding testosterone production.
SERMs are essential for any PCT.
Aromatase Inhibitors
Aromasin (Exemestane), Arimidex (Anastrozole), and Letrozole (Femara).
These inhibit the aromatase enzyme, lowering estrogen levels in the body. This reduction in estrogen promotes the release of LH and FSH.
However, Arimidex and Letrozole interact negatively with Nolvadex, so Aromasin should be the choice for PCT.
Aromasin does not interact with Nolvadex, has less of a negative impact on cholesterol, and effectively raises testosterone levels.
HCG
HCG acts as a synthetic LH, stimulating the testes to promote testosterone production.
However, it can trigger the negative feedback loop and should not be used alone; it must be paired with an aromatase inhibitor.
HCG increases testicular aromatase activity, which raises estrogen levels. To prevent this side effect, Aromasin should be used.
HCG should be administered at the beginning of PCT for 1-2 weeks at a dose of 100-1,500 IU every other day, and then discontinued.
SERMs: Nolvadex vs. Clomid
Nolvadex works synergistically with HCG and helps prevent testicular desensitization.
It is also more effective and cost-efficient than Clomid at stimulating endogenous testosterone production.
Clomid exhibits some estrogenic action in the pituitary, which can trigger negative feedback.
In contrast, Nolvadex provides nearly 100% estrogen antagonism in the pituitary.
The standard dosage for Nolvadex is 20-40mg per day, with 40mg being taken for the first 1-2 weeks for faster recovery.
Conclusion
The Ideal Post Cycle Therapy Protocol
Total PCT Duration: 4 – 6 Weeks (depending on individual recovery)
|
Weeks 1-2 |
– HCG: 1000iu / every other day – Aromasin (Exemestane): 25mg / day – Nolvadex (Tamoxifen Citrate): 40mg / day |
|
Weeks 2-6 |
– Nolvadex (Tamoxifen Citrate): 20mg / day |
Optional Ancillary Compounds During PCT (Vitamins/Supplements/Drugs)
Vitamin D (Cholecalciferol) has been shown in studies to increase testosterone levels and inhibit SHBG in men when used at high doses.
There are also many clinical studies showing that low Vitamin D levels lead to decreased endogenous testosterone production.
For instance, a study in Austria with about 200 subjects showed that the group taking 3332 IU of Vitamin D daily had higher testosterone levels and lower SHBG compared to the placebo group.
Androgen levels and Vitamin D levels show a seasonal correlation, and multiple studies have confirmed that Vitamin D supplementation increases testosterone levels and reduces SHBG.
There is also anecdotal evidence of individuals experiencing increased testosterone levels within 1-2 months of supplementing with Vitamin D.
